ECM
TVTX icon

Element Capital Management’s Travere Therapeutics TVTX Stock Holding History

Element Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-48,095
Closed -$1.38M – 891
2018
Q3 		$1.38M Buy
+48,095
New +$1.37M 0.03% 320

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Element Capital Management's TVTX Position: Q4 2018 in Review

Element Capital Management sold out of Travere Therapeutics (TVTX) in Q4 2018, closing a stake of 48,095 shares — an estimated $1.38M sold.

Element Capital Management first reported a position in TVTX in Q3 2018 and held it in 1 quarter. The position peaked at $1.38M in Q3 2018. 130 funds tracked by Wall St. Rank hold TVTX as of Q4 2018.

  • Element Capital Management reported no remaining Travere Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Element Capital Management sold 48,095 Travere Therapeutics shares in Q4 2018, an estimated $1.38M.
  • Element Capital Management first reported a position in Travere Therapeutics in Q3 2018 and held it in 1 quarter.
  • Element Capital Management's Travere Therapeutics position peaked at $1.38M in Q3 2018.
  • 130 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2018.

Based on Element Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.